SMYD3 and hepatocellular carcinoma: Hamamoto et al. initially characterized SMYD3 overexpression and its oncogenic functions in HCC and CRC [6]; subsequently, several groups demonstrated that upregulated SMYD3 promotes tumorigenicity and metastasis in various GI cancer types.